Rockstar Games Studios, owned by Take-Two Interactive, postpones release of Grand Theft Auto VI to May 2026 from fall 2025, impacting stock and company expectations.
On the daily interval, the /ES is trading above the Quarter's developing value area, suggesting the path of least resistance remains to the upside, potentially targeting the previous Quarter's VAL close around 5759.
In a strategic move, Alibaba Group Holding (NYSE: BABA) has advanced the rollout of its rapid-delivery service, Taobao Instant Commerce. This accelerates the rivalry with JD.com (NASDAQ: JD)and Meituan.
SMITHFIELD FOODS INC has caught the attention as a great value stock. NASDAQ:SFD excels in profitability, solvency, and liquidity, all while being very reasonably priced.
Cigna posts strong Q1 results with rising sales at Evernorth and Cigna Healthcare; raises 2025 EPS outlook to $29.60 amid higher medical cost ratio expectations.
QIFU TECHNOLOGY INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:QFIN showcases decent financial health and profitability, coupled with an attractive price.
Aptos (CRYPTO: APT) is expanding its scope beyond traditional crypto verticals like DeFi and NFTs, with a growing focus on real-world consumer applications, particularly in payments, HR
Lynch encouraged investors to look at businesses they understand and have strong financials. Does APPLIED MATERIALS INC (NASDAQ:AMAT) align with this approach? We take a closer look.
Eyes will be on the OPEC meeting May 5th where it's rumoured Saudi will push for more production increases, (by 400,000 bbl pd) as the USA saw it's first contraction in economic growth in three years.
Legendary investors Warren Buffett and Cathie Wood have vastly different strategies - steady compounders vs volatile visionaries. Who would you rather be?
Uncover the potential of PERDOCEO EDUCATION CORP, an undervalued stock. NASDAQ:PRDO maintains a strong financial position and offers an appealing valuation.
AstraZeneca said on Friday that the full results from the two trials will be shared with regulatory authorities and presented at an upcoming medical meeting.
JPMorgan analyst favors EVgo over ChargePoint, citing stronger partnerships and utilization. Tariffs could hurt both, but EVgo has potential for growth.
